Reformulating pediatric pharmaceutical commercialization
Clinicians who treat children often find that the only devices and drugs available to them have been designed or sized for adults. Various FDA studies, for example, have shown that as much as 70 percent of the medicines prescribed to children may have been dispensed off label, without proper pediatric dosing information. As a result, advancing pediatric innovations is one of the health industry’s greatest challenges.
The Kauffman Foundation provided the seed funding to create a novel solution—a public/private/for-profit/nonprofit collaboration called the
Institute for Pediatric Innovation (IPI). The IPI was founded to help translate new pediatric products into viable commercial opportunities that companies will adopt.
This unique nonprofit consortium includes pediatric care and research centers, a resource network of people and organizations with expertise in commercial development of medical products, and an action plan focused on near-term product opportunities that will create the conditions for developing pediatric products. The goal is to develop pediatric pharmaceutical reformulation initiatives that ultimately will result in products for follow-on commercial funding.
